Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis
The term heparin resistance (HR) is used by clinicians without specific criteria. We performed a literature search and surveyed our SSC membership to better define the term when applied to medical and intensive care unit patients. The most common heparin dosing strategy reported in the literature (5...
Gespeichert in:
Veröffentlicht in: | Journal of thrombosis and haemostasis 2023-12, Vol.21 (12), p.3649-3657 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3657 |
---|---|
container_issue | 12 |
container_start_page | 3649 |
container_title | Journal of thrombosis and haemostasis |
container_volume | 21 |
creator | Levy, Jerrold H. Sniecinski, Roman M. Rocca, Bianca Ghadimi, Kamrouz Douketis, James Frere, Corinne Helms, Julie Iba, Toshiaki Koster, Andreas Lech, Tara K. Maier, Cheryl L. Neal, Mathew D. Scarlestscu, Ecatarina Spyropoulos, Alex Steiner, Marie E. Tafur, Alfonso J. Tanaka, Kenichi A. Connors, Jean M. |
description | The term heparin resistance (HR) is used by clinicians without specific criteria. We performed a literature search and surveyed our SSC membership to better define the term when applied to medical and intensive care unit patients. The most common heparin dosing strategy reported in the literature (53%) and by survey respondents (80.4%) was the use of weight-based dosing. Heparin monitoring results were similar based on the proportion of publications and respondents that reported the use of anti-Xa and activated partial thromboplastin time. The most common literature definition of HR was >35 000 U/d, but no consensus was reported among survey respondents regarding weight-based and the total dose of heparin when determining resistance. Respondent consensus on treating HR included antithrombin supplementation, direct thrombin inhibitors, or administering more heparin as the strategies available for treating HR. A range of definitions for HR exist. Given the common use of heparin weight-based dosing, future publications employing the term HR should include weight-based definitions, monitoring assay, and target level used. Further work is needed to develop a consensus for defining HR.
•The term heparin resistance is commonly used without a specific definition or clarity.•We performed a literature search and Scientific and Standardization Committee survey to identify published definitions and current clinical practice definitions of heparin resistance.•Definitions varied widely, with heterogeneity in total threshold heparin doses, weight-based dosing, and management.•Further work is needed to develop a consensus for the definition of heparin resistance. |
doi_str_mv | 10.1016/j.jtha.2023.08.013 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2857840373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1538783623006414</els_id><sourcerecordid>2857840373</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-7c01b81ca6fc6c6a701799ec930fc7c4a753fb7f1e6701ab1f1c58127898e5d73</originalsourceid><addsrcrecordid>eNp9kMtOxCAUhonReH8BF4alm6lQpoUaN6ZexsREkxnXhNKDw2RaRqAmvoDPLeOoceUKyPn-_4QPoRNKMkpoeb7IFnGuspzkLCMiI5RtoX1aMDHigpXbf-576CCEBSG0KnKyi_YYL2lVVuN99HENxva2f8FzWClve-wh2BBVr-ECa9d1Q2-1itb12HjX4TgHfD-dTfB0WuPp0KwRGyMAdgY_gbduBT7xb4BV3-La25jyS1wrD3g2TxWNSwu-hhPoXFqVnkdox6hlgOPv8xA9397M6sno4fHuvr56GOkxIXHENaGNoFqVRpe6VJxQXlWgK0aM5nqseMFMww2FMo1UQw3VhaA5F5WAouXsEJ1telfevQ4Qouxs0LBcqh7cEGQuCi7GhHGW0HyDau9C8GDkyttO-XdJiVz7lwu59i_X_iURMvlPodPv_qHpoP2N_AhPwOUGgPTLNwteBm0hyW6tBx1l6-x__Z8XQZiM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2857840373</pqid></control><display><type>article</type><title>Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Levy, Jerrold H. ; Sniecinski, Roman M. ; Rocca, Bianca ; Ghadimi, Kamrouz ; Douketis, James ; Frere, Corinne ; Helms, Julie ; Iba, Toshiaki ; Koster, Andreas ; Lech, Tara K. ; Maier, Cheryl L. ; Neal, Mathew D. ; Scarlestscu, Ecatarina ; Spyropoulos, Alex ; Steiner, Marie E. ; Tafur, Alfonso J. ; Tanaka, Kenichi A. ; Connors, Jean M.</creator><creatorcontrib>Levy, Jerrold H. ; Sniecinski, Roman M. ; Rocca, Bianca ; Ghadimi, Kamrouz ; Douketis, James ; Frere, Corinne ; Helms, Julie ; Iba, Toshiaki ; Koster, Andreas ; Lech, Tara K. ; Maier, Cheryl L. ; Neal, Mathew D. ; Scarlestscu, Ecatarina ; Spyropoulos, Alex ; Steiner, Marie E. ; Tafur, Alfonso J. ; Tanaka, Kenichi A. ; Connors, Jean M.</creatorcontrib><description>The term heparin resistance (HR) is used by clinicians without specific criteria. We performed a literature search and surveyed our SSC membership to better define the term when applied to medical and intensive care unit patients. The most common heparin dosing strategy reported in the literature (53%) and by survey respondents (80.4%) was the use of weight-based dosing. Heparin monitoring results were similar based on the proportion of publications and respondents that reported the use of anti-Xa and activated partial thromboplastin time. The most common literature definition of HR was >35 000 U/d, but no consensus was reported among survey respondents regarding weight-based and the total dose of heparin when determining resistance. Respondent consensus on treating HR included antithrombin supplementation, direct thrombin inhibitors, or administering more heparin as the strategies available for treating HR. A range of definitions for HR exist. Given the common use of heparin weight-based dosing, future publications employing the term HR should include weight-based definitions, monitoring assay, and target level used. Further work is needed to develop a consensus for defining HR.
•The term heparin resistance is commonly used without a specific definition or clarity.•We performed a literature search and Scientific and Standardization Committee survey to identify published definitions and current clinical practice definitions of heparin resistance.•Definitions varied widely, with heterogeneity in total threshold heparin doses, weight-based dosing, and management.•Further work is needed to develop a consensus for the definition of heparin resistance.</description><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1016/j.jtha.2023.08.013</identifier><identifier>PMID: 37619694</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Anticoagulants - adverse effects ; anticoagulation ; Antithrombins - therapeutic use ; Communication ; COVID-19 ; Critical Care ; ECMO ; Hemostasis ; heparin ; Heparin - adverse effects ; Humans ; Partial Thromboplastin Time ; resistance ; sensitivity ; Thrombosis - drug therapy</subject><ispartof>Journal of thrombosis and haemostasis, 2023-12, Vol.21 (12), p.3649-3657</ispartof><rights>2023 International Society on Thrombosis and Haemostasis</rights><rights>Copyright © 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-7c01b81ca6fc6c6a701799ec930fc7c4a753fb7f1e6701ab1f1c58127898e5d73</citedby><cites>FETCH-LOGICAL-c400t-7c01b81ca6fc6c6a701799ec930fc7c4a753fb7f1e6701ab1f1c58127898e5d73</cites><orcidid>0000-0001-6025-1379 ; 0000-0002-3175-461X ; 0000-0001-8304-6423 ; 0000-0002-9287-7541 ; 0000-0002-0255-4088 ; 0000-0002-5051-1365 ; 0000-0002-5556-3623 ; 0000-0001-9713-6403 ; 0000-0003-3766-4962 ; 0009-0006-1186-7808 ; 0000-0002-0179-1903 ; 0000-0001-6445-582X ; 0000-0003-4044-2674 ; 0000-0001-6303-4732 ; 0000-0003-4766-3314 ; 0000-0003-4169-1920 ; 0000-0001-5288-0394 ; 0000-0003-0895-6800</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37619694$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Levy, Jerrold H.</creatorcontrib><creatorcontrib>Sniecinski, Roman M.</creatorcontrib><creatorcontrib>Rocca, Bianca</creatorcontrib><creatorcontrib>Ghadimi, Kamrouz</creatorcontrib><creatorcontrib>Douketis, James</creatorcontrib><creatorcontrib>Frere, Corinne</creatorcontrib><creatorcontrib>Helms, Julie</creatorcontrib><creatorcontrib>Iba, Toshiaki</creatorcontrib><creatorcontrib>Koster, Andreas</creatorcontrib><creatorcontrib>Lech, Tara K.</creatorcontrib><creatorcontrib>Maier, Cheryl L.</creatorcontrib><creatorcontrib>Neal, Mathew D.</creatorcontrib><creatorcontrib>Scarlestscu, Ecatarina</creatorcontrib><creatorcontrib>Spyropoulos, Alex</creatorcontrib><creatorcontrib>Steiner, Marie E.</creatorcontrib><creatorcontrib>Tafur, Alfonso J.</creatorcontrib><creatorcontrib>Tanaka, Kenichi A.</creatorcontrib><creatorcontrib>Connors, Jean M.</creatorcontrib><title>Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>The term heparin resistance (HR) is used by clinicians without specific criteria. We performed a literature search and surveyed our SSC membership to better define the term when applied to medical and intensive care unit patients. The most common heparin dosing strategy reported in the literature (53%) and by survey respondents (80.4%) was the use of weight-based dosing. Heparin monitoring results were similar based on the proportion of publications and respondents that reported the use of anti-Xa and activated partial thromboplastin time. The most common literature definition of HR was >35 000 U/d, but no consensus was reported among survey respondents regarding weight-based and the total dose of heparin when determining resistance. Respondent consensus on treating HR included antithrombin supplementation, direct thrombin inhibitors, or administering more heparin as the strategies available for treating HR. A range of definitions for HR exist. Given the common use of heparin weight-based dosing, future publications employing the term HR should include weight-based definitions, monitoring assay, and target level used. Further work is needed to develop a consensus for defining HR.
•The term heparin resistance is commonly used without a specific definition or clarity.•We performed a literature search and Scientific and Standardization Committee survey to identify published definitions and current clinical practice definitions of heparin resistance.•Definitions varied widely, with heterogeneity in total threshold heparin doses, weight-based dosing, and management.•Further work is needed to develop a consensus for the definition of heparin resistance.</description><subject>Anticoagulants - adverse effects</subject><subject>anticoagulation</subject><subject>Antithrombins - therapeutic use</subject><subject>Communication</subject><subject>COVID-19</subject><subject>Critical Care</subject><subject>ECMO</subject><subject>Hemostasis</subject><subject>heparin</subject><subject>Heparin - adverse effects</subject><subject>Humans</subject><subject>Partial Thromboplastin Time</subject><subject>resistance</subject><subject>sensitivity</subject><subject>Thrombosis - drug therapy</subject><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOxCAUhonReH8BF4alm6lQpoUaN6ZexsREkxnXhNKDw2RaRqAmvoDPLeOoceUKyPn-_4QPoRNKMkpoeb7IFnGuspzkLCMiI5RtoX1aMDHigpXbf-576CCEBSG0KnKyi_YYL2lVVuN99HENxva2f8FzWClve-wh2BBVr-ECa9d1Q2-1itb12HjX4TgHfD-dTfB0WuPp0KwRGyMAdgY_gbduBT7xb4BV3-La25jyS1wrD3g2TxWNSwu-hhPoXFqVnkdox6hlgOPv8xA9397M6sno4fHuvr56GOkxIXHENaGNoFqVRpe6VJxQXlWgK0aM5nqseMFMww2FMo1UQw3VhaA5F5WAouXsEJ1telfevQ4Qouxs0LBcqh7cEGQuCi7GhHGW0HyDau9C8GDkyttO-XdJiVz7lwu59i_X_iURMvlPodPv_qHpoP2N_AhPwOUGgPTLNwteBm0hyW6tBx1l6-x__Z8XQZiM</recordid><startdate>202312</startdate><enddate>202312</enddate><creator>Levy, Jerrold H.</creator><creator>Sniecinski, Roman M.</creator><creator>Rocca, Bianca</creator><creator>Ghadimi, Kamrouz</creator><creator>Douketis, James</creator><creator>Frere, Corinne</creator><creator>Helms, Julie</creator><creator>Iba, Toshiaki</creator><creator>Koster, Andreas</creator><creator>Lech, Tara K.</creator><creator>Maier, Cheryl L.</creator><creator>Neal, Mathew D.</creator><creator>Scarlestscu, Ecatarina</creator><creator>Spyropoulos, Alex</creator><creator>Steiner, Marie E.</creator><creator>Tafur, Alfonso J.</creator><creator>Tanaka, Kenichi A.</creator><creator>Connors, Jean M.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6025-1379</orcidid><orcidid>https://orcid.org/0000-0002-3175-461X</orcidid><orcidid>https://orcid.org/0000-0001-8304-6423</orcidid><orcidid>https://orcid.org/0000-0002-9287-7541</orcidid><orcidid>https://orcid.org/0000-0002-0255-4088</orcidid><orcidid>https://orcid.org/0000-0002-5051-1365</orcidid><orcidid>https://orcid.org/0000-0002-5556-3623</orcidid><orcidid>https://orcid.org/0000-0001-9713-6403</orcidid><orcidid>https://orcid.org/0000-0003-3766-4962</orcidid><orcidid>https://orcid.org/0009-0006-1186-7808</orcidid><orcidid>https://orcid.org/0000-0002-0179-1903</orcidid><orcidid>https://orcid.org/0000-0001-6445-582X</orcidid><orcidid>https://orcid.org/0000-0003-4044-2674</orcidid><orcidid>https://orcid.org/0000-0001-6303-4732</orcidid><orcidid>https://orcid.org/0000-0003-4766-3314</orcidid><orcidid>https://orcid.org/0000-0003-4169-1920</orcidid><orcidid>https://orcid.org/0000-0001-5288-0394</orcidid><orcidid>https://orcid.org/0000-0003-0895-6800</orcidid></search><sort><creationdate>202312</creationdate><title>Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis</title><author>Levy, Jerrold H. ; Sniecinski, Roman M. ; Rocca, Bianca ; Ghadimi, Kamrouz ; Douketis, James ; Frere, Corinne ; Helms, Julie ; Iba, Toshiaki ; Koster, Andreas ; Lech, Tara K. ; Maier, Cheryl L. ; Neal, Mathew D. ; Scarlestscu, Ecatarina ; Spyropoulos, Alex ; Steiner, Marie E. ; Tafur, Alfonso J. ; Tanaka, Kenichi A. ; Connors, Jean M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-7c01b81ca6fc6c6a701799ec930fc7c4a753fb7f1e6701ab1f1c58127898e5d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anticoagulants - adverse effects</topic><topic>anticoagulation</topic><topic>Antithrombins - therapeutic use</topic><topic>Communication</topic><topic>COVID-19</topic><topic>Critical Care</topic><topic>ECMO</topic><topic>Hemostasis</topic><topic>heparin</topic><topic>Heparin - adverse effects</topic><topic>Humans</topic><topic>Partial Thromboplastin Time</topic><topic>resistance</topic><topic>sensitivity</topic><topic>Thrombosis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Levy, Jerrold H.</creatorcontrib><creatorcontrib>Sniecinski, Roman M.</creatorcontrib><creatorcontrib>Rocca, Bianca</creatorcontrib><creatorcontrib>Ghadimi, Kamrouz</creatorcontrib><creatorcontrib>Douketis, James</creatorcontrib><creatorcontrib>Frere, Corinne</creatorcontrib><creatorcontrib>Helms, Julie</creatorcontrib><creatorcontrib>Iba, Toshiaki</creatorcontrib><creatorcontrib>Koster, Andreas</creatorcontrib><creatorcontrib>Lech, Tara K.</creatorcontrib><creatorcontrib>Maier, Cheryl L.</creatorcontrib><creatorcontrib>Neal, Mathew D.</creatorcontrib><creatorcontrib>Scarlestscu, Ecatarina</creatorcontrib><creatorcontrib>Spyropoulos, Alex</creatorcontrib><creatorcontrib>Steiner, Marie E.</creatorcontrib><creatorcontrib>Tafur, Alfonso J.</creatorcontrib><creatorcontrib>Tanaka, Kenichi A.</creatorcontrib><creatorcontrib>Connors, Jean M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Levy, Jerrold H.</au><au>Sniecinski, Roman M.</au><au>Rocca, Bianca</au><au>Ghadimi, Kamrouz</au><au>Douketis, James</au><au>Frere, Corinne</au><au>Helms, Julie</au><au>Iba, Toshiaki</au><au>Koster, Andreas</au><au>Lech, Tara K.</au><au>Maier, Cheryl L.</au><au>Neal, Mathew D.</au><au>Scarlestscu, Ecatarina</au><au>Spyropoulos, Alex</au><au>Steiner, Marie E.</au><au>Tafur, Alfonso J.</au><au>Tanaka, Kenichi A.</au><au>Connors, Jean M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2023-12</date><risdate>2023</risdate><volume>21</volume><issue>12</issue><spage>3649</spage><epage>3657</epage><pages>3649-3657</pages><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>The term heparin resistance (HR) is used by clinicians without specific criteria. We performed a literature search and surveyed our SSC membership to better define the term when applied to medical and intensive care unit patients. The most common heparin dosing strategy reported in the literature (53%) and by survey respondents (80.4%) was the use of weight-based dosing. Heparin monitoring results were similar based on the proportion of publications and respondents that reported the use of anti-Xa and activated partial thromboplastin time. The most common literature definition of HR was >35 000 U/d, but no consensus was reported among survey respondents regarding weight-based and the total dose of heparin when determining resistance. Respondent consensus on treating HR included antithrombin supplementation, direct thrombin inhibitors, or administering more heparin as the strategies available for treating HR. A range of definitions for HR exist. Given the common use of heparin weight-based dosing, future publications employing the term HR should include weight-based definitions, monitoring assay, and target level used. Further work is needed to develop a consensus for defining HR.
•The term heparin resistance is commonly used without a specific definition or clarity.•We performed a literature search and Scientific and Standardization Committee survey to identify published definitions and current clinical practice definitions of heparin resistance.•Definitions varied widely, with heterogeneity in total threshold heparin doses, weight-based dosing, and management.•Further work is needed to develop a consensus for the definition of heparin resistance.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>37619694</pmid><doi>10.1016/j.jtha.2023.08.013</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6025-1379</orcidid><orcidid>https://orcid.org/0000-0002-3175-461X</orcidid><orcidid>https://orcid.org/0000-0001-8304-6423</orcidid><orcidid>https://orcid.org/0000-0002-9287-7541</orcidid><orcidid>https://orcid.org/0000-0002-0255-4088</orcidid><orcidid>https://orcid.org/0000-0002-5051-1365</orcidid><orcidid>https://orcid.org/0000-0002-5556-3623</orcidid><orcidid>https://orcid.org/0000-0001-9713-6403</orcidid><orcidid>https://orcid.org/0000-0003-3766-4962</orcidid><orcidid>https://orcid.org/0009-0006-1186-7808</orcidid><orcidid>https://orcid.org/0000-0002-0179-1903</orcidid><orcidid>https://orcid.org/0000-0001-6445-582X</orcidid><orcidid>https://orcid.org/0000-0003-4044-2674</orcidid><orcidid>https://orcid.org/0000-0001-6303-4732</orcidid><orcidid>https://orcid.org/0000-0003-4766-3314</orcidid><orcidid>https://orcid.org/0000-0003-4169-1920</orcidid><orcidid>https://orcid.org/0000-0001-5288-0394</orcidid><orcidid>https://orcid.org/0000-0003-0895-6800</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1538-7836 |
ispartof | Journal of thrombosis and haemostasis, 2023-12, Vol.21 (12), p.3649-3657 |
issn | 1538-7836 1538-7836 |
language | eng |
recordid | cdi_proquest_miscellaneous_2857840373 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Anticoagulants - adverse effects anticoagulation Antithrombins - therapeutic use Communication COVID-19 Critical Care ECMO Hemostasis heparin Heparin - adverse effects Humans Partial Thromboplastin Time resistance sensitivity Thrombosis - drug therapy |
title | Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T01%3A58%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Defining%20heparin%20resistance:%20communication%20from%20the%20ISTH%20SSC%20Subcommittee%20of%20Perioperative%20and%20Critical%20Care%20Thrombosis%20and%20Hemostasis&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=Levy,%20Jerrold%20H.&rft.date=2023-12&rft.volume=21&rft.issue=12&rft.spage=3649&rft.epage=3657&rft.pages=3649-3657&rft.issn=1538-7836&rft.eissn=1538-7836&rft_id=info:doi/10.1016/j.jtha.2023.08.013&rft_dat=%3Cproquest_cross%3E2857840373%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2857840373&rft_id=info:pmid/37619694&rft_els_id=S1538783623006414&rfr_iscdi=true |